Soley Therapeutics

Soley Therapeutics

Private
South San Francisco, CaliforniaHealthcare & Life Scienceshttps://www.soleytherapeutics.com

Last Round

Series C

Jan 7, 2026

Total Funding Raised

$220M

Company Overview

Soley Therapeutics is a biotechnology company focused on creating innovative therapies for complex diseases that resist standard treatments.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology, Medical AI, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting

AI Layer

Application

Keywords

AI drug discoverydrug discovery platformtechbioAI biotechphenotypic drug discoveryhigh-throughput screeninginternal therapeutic pipelinepharmaceutical partnershipsprecision medicineoncology therapeuticscellular response analysisbiopharma licensingcardiovascular medicine

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Soley Therapeutics Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Soley Therapeutics Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series CJan 7, 2026
Series ADec 22, 2020

Key People

Founding team and executive leadership

Kurosh Ameri

Founder Co-founder, Chief Scientific Officer, Soley Therapeutics, Inc.

Founding Team

Yerem Yeghiazarians

Soley Therapeutics, Inc. - CEO, Co-Founder, Board Member

Founding Team

Soley Therapeutics Investors

Notable investors and investment history

InvestorRounds
Breyer CapitalSeries C, Series A
GordonMD Global InvestmentsSeries C, Series A
HRTG PartnersSeries C
RWN ManagementSeries C
Surveyor CapitalSeries C

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 17, 2026

    Preclinical data for STX-6398 presented at AACR Annual Meeting 2026.

  • Mar 18, 2026

    STX-6398 targets undruggable CKAP2 for selective anti-tumor activity.

Soley Therapeutics Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Soley Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Soley Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersSouth San Francisco, California
Employee Range36
Year Founded2020
Last FundingJan 7, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.